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Background: Sepsis continues to be a poorly understood syndrome with a high mortality rate. While we are
beginning to decipher the intricate interplay of the inflammatory response during sepsis, the precise regulation of
the hypothalamic-pituitary-adrenal (HPA) axis and its impact on electrolyte homeostasis during sepsis remains
incompletely understood.
Methods: Sepsis was induced in adult male Sprague-Dawley rats by cecal ligation and puncture (CLP). Plasma
samples were obtained as a function of time (6-48 hrs) after CLP and compared with healthy animals (neg ctrl).
Samples were analyzed for adrenocorticotropin (ACTH), corticosterone, and aldosterone levels, as well as
concentrations of sodium (Na
+), potassium (K
+), chloride (Cl
-), and magnesium (Mg
2+).
Results: ACTH levels were found to be significantly reduced 6-24 hrs after CLP in comparison to baseline levels and
displayed gradual recovery during the later course (24-48 hrs) of sepsis. Plasma corticosterone concentrations exhibited
a bell-shaped response, peaking between 6 and 12 hrs followed by rapid decline and concentrations below negative
control levels 48 hrs after injury. Aldosterone levels in septic animals were continuously elevated between 6 and 48 hrs.
Whereas plasma Na




significantly reduced as a function of time and gradually recovered during the later course of sepsis.
Conclusions: CLP-induced sepsis resulted in dynamic changes of ACTH, corticosterone, and aldosterone levels. In
addition, electrolyte levels showed significant disturbances after CLP. These electrolyte perturbations might be
evoked by a downstream effect or a dysfunctional HPA-axis response during sepsis and contribute to severe
complications during sepsis.
Introduction
Sepsis remains an enigmatic, poorly understood disease [1].
Disturbingly, there has been a rapid increase of hospitaliza-
tion and mortality rates between 1993 and 2003 [2], mak-
ing sepsis the tenth leading cause of death in the United
States [3]. Despite numerous encouraging preclinical
results for new therapeutic approaches to sepsis, a success-
ful transfer from “bench to bedside” has yet to be achieved
[4-10]. Various randomized clinical trials investigating anti-
inflammatory strategies have failed to show any survival
improvement [11]. To date, the only clearly beneficial
treatment for the septic patient is early goal-directed
therapy [12].
During an immune response, the central nervous and
immune system extensively communicate with each
other [13]. The major pathways involved in this cross-
talk are the hypothalamic-pituitary-adrenal (HPA) axis
and the autonomic nervous system [13-15]. Immune
mediators and cytokines released by the innate immune
system trigger regional neural and systemic neuroendo-
crine responses, both of which seek to return the system
to a homeostatic state [13]. Steroids are hormonal key
players antagonizing and down-regulating inflammation
[16]. However, during sepsis, the HPA axis may become
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provided the original work is properly cited.severely dysfunctional [13,17]. In humans, sepsis is
known to induce an abnormal pituitary response, result-
ing in profound hormonal changes in ACTH, growth
hormone, vasopressin, cortisol, mineralocorticoids, and
thyroid hormones [18,19].
Vermes and colleagues studied regulatory mechanisms
of the hypothalamo-pituitary-adrenal system in critically ill
patients and found elevated plasma levels of cortisol and
ACTH in septic and trauma patients [20]. Whereas plasma
concentrations of cortisol remained elevated for 8 days,
plasma ACTH decreased between days 3 to 5. Plasma
levels of endothelin-1 and atrial natriuretic hormone were
significantly elevated during the entire observation period.
Accordingly, the authors speculated that the high endothe-
lin-1 level may exert a positive drive on the adrenocortical
level, whereas elevated high ANH level may inhibit the
HPA axis during critical illness. Thus, critically ill patients
can develop metabolic alkalosis, hyperreninemic hyperal-
dosteronism, and hypokalemia.
Many reports about the HPA axis during sepsis repre-
sent “snapshot” measurements of HPA axis function,
rather than a methodical assessment as a function of time,
and are mostly performed following ACTH stimulation
tests [21]. Moreover, most of the literature focuses on the
anti-inflammatory properties of adrenal-derived glucocor-
ticoids. A thorough evaluation of the downstream events
triggered by a dysfunctional aldosterone response, such as
severely altered electrolyte homeostasis, has yet to be
investigated.
In the present study, we sought to investigate the pitui-
tary-adrenal-electrolyte axis in experimental CLP-induced
sepsis in a systematic approach. In parallel with the exist-
ing human studies, we hypothesized that the HPA axis




All procedures were performed in accordance with the
National Institutes of Health guidelines and University
Committee on Use and Care of Animals, University of
Michigan (UCUCA approval #8575). Specific pathogen-
free, adult male Sprague-Dawley rats (Harlan Inc., Indiana-
polis, IN) weighing 300-350 g were used in all experi-
ments. Sepsis was induced by the CLP procedure as
previously described [22,23]. In brief, rats were anesthe-
tized with isoflurane (3%, oxygen flow 3L O2/min). After
abdominal midline incision, the cecum was exposed,
ligated, and punctured through and through with an 18-
gauge needle, and a small portion of feces was expressed
to ensure patency of the punctures. After repositioning of
the bowel, the abdomen was closed in layers using 4-0 sur-
gical sutures (Ethicon Inc., Somerville, NJ) and metallic
clips. Sham animals underwent the same procedure except
for ligation and puncture of the cecum. Before and after
the surgery, animals had unrestricted access to food and
water.
Plasma isolation
Rat whole blood was collected into syringes containing
anticoagulant citrate dextrose (ACD; Baxter, Deerfield, IL)
i na9 : 1r a t i ob yp u n c t u r eo ft h ei n f e r i o rv e n ac a v aa sa
function of time after CLP surgery. Samples were centri-
fuged (2,500 rpm, 10 min, 4°C) and plasma was obtained
and immediately stored at -80°C until further analysis.
Because ACTH and corticosterone are released in a circa-
dian fashion, peaking between 8-9 PM in night-active
rodents [24], all samples were obtained at 8 PM to avoid
baseline fluctuations.
ELISA analysis of rat ACTH, rat corticosterone, and rat
aldosterone
Levels of ACTH, corticosterone, and aldosterone were
determined by using commercially available ELISA kits
(ACTH: Phoenix Pharmaceuticals, Belmont, CA; Corticos-
terone: Diagnostic Systems, Webster, TX; Aldosterone:
Cayman Chemical, Ann Arbor, MI) according to the man-
ufacturer’s instructions. The ACTH ELISA had a mini-
mum detectable concentration of 0.08 ng/ml and a range
from 0-25 ng/ml. The Corticosterone EIA had a minimum
detectable concentration of 1.6 (range, 6-2000) ng/ml, and
the Aldosterone assay had a minimum detectable concen-
tration of 21 (range, 7.8-1000) pg/ml. Assays were per-
formed strictly according to the manufacturer’s
instructions.
Assessment of plasma electrolyte levels
After plasma isolation, samples were run on a standar-
dized chemistry analyzer, which applies plasma directly
to individually wrapped slides (“Vettest 8008” chemistry
analyzer, IDEXX Laboratories, Inc., Westbrook, ME).
Any needed dilutions were performed with 0.9% NaCl.
Electrolyte levels were then directly evaluated by the
companion standardized IDEXX VetLyte analyzer
(IDEXX Laboratories, Inc.).
Statistical analysis
All values are expressed as means ± SEM. Data were ana-
lyzed with a one-way ANOVA, and individual group
means were then compared with the Tukey multiple
comparison test. Differences were considered statistically
significant at P < 0.05.
Results
Experimental sepsis induces severe depression of
systemic ACTH levels
P l a s m aw a si s o l a t e df r o mw h o l eb l o o df r o mh e a l t h y
negative control animals (neg ctrl) or CLP rats, and
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shown in Figure 1A, there was a substantial reduction in
ACTH levels in plasma after CLP. Whereas negative
control levels of ACTH ranged at 3 ng/ml, CLP induced
a highly significant reduction of plasma ACTH levels
between 6 hrs and 24 hrs after induction of sepsis, with
a nadir 12 hrs after CLP surgery (~0.3 ng/ml). After 48
hrs, ACTH levels gradually returned to levels found in
negative controls.
Transient hypercortisolism with subsequent
corticosterone deficiency in plasma during CLP
Corticosterone represents the major glucocorticoid of
rodents [25]. Plasma samples were assessed for corticos-
terone as a function of time after CLP and revealed a
bell-shaped response (Figure 1B). Initially, hypercortico-
solism was observed during the early course of experi-
mental sepsis (6-24 hrs), with peak levels (~900 pg/ml)
reaching more than threefold elevated concentrations
compared with neg ctrl levels (~220 pg/ml). During the
late course of CLP-induced sepsis (48 hrs), rats presented
with significantly reduced corticosterone levels of
150 pg/ml in comparison to neg ctrl animals.
Hyperaldosteronism after CLP-induced sepsis
Plasma levels of aldosterone were determined in neg ctrl
animals or septic rats, as a function of time after CLP
by ELISA analysis. During the complete observation
time following CLP (6-48 hrs), aldosterone levels were
found to be significantly elevated after CLP-induced sep-
sis, peaking between 6-24 hrs, where levels were found
to be greater than fourfold increased compared with the
neg ctrl group (Figure 1C).
Electrolyte disturbances during sepsis
Plasma samples were obtained from healthy, negative
control animals and animals subjected to CLP and evalu-





2+) levels (Figure 2). Na
+ levels were




Figure 1 Hormonal changes of the HPA-axis following experimental sepsis. (A) Plasma levels obtained from healthy rats (neg ctrl) or septic
littermates (6-48 hrs after CLP). (B) Plasma samples from septic animals were obtained 6-48 hrs after CLP and compared with healthy rats. (C)
Aldosterone concentrations were assessed as a function of time in septic vs. healthy rats. All samples were analyzed by ELISA. n = 5-10 per
experimental condition.
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L in neg ctrl animals) (A). In contrast, K
+ concentrations
in septic rats were significantly reduced 6-24 hrs after
CLP compared with neg ctrl rats (4 mmol/L vs. 2.7
mmol/L) and returned to negative control levels 48 hrs
after injury (B). During the entire course of observation,
septic rats displayed significantly reduced levels of Cl
-
compared with healthy animals, reaching a nadir 12 hrs
after CLP (75 mmol/L vs. 52 mmol/L) (C). Plasma levels
of Mg
2+ initially decreased significantly 6-12 hrs after
CLP (0.75 mg/dl) and returned to negative control
levels (1.3 mg/dl) 24 hrs after induction of experimental
sepsis (D).
Discussion
Despite advanced, aggressive ICU management of the
septic patient, lethality rates remain at 40-60% for
patients in septic shock [26]. Multiple promising
experimental approaches have failed to show a suc-
cessful therapeutic translation into humans [10]. Initi-
ally, these failures might have been attributable to an
overly simplified theoretical understanding of sepsis as
a merely proinflammatory state [27]. Subsequently,
this notion has been challenged [28], requiring a care-
ful reconsideration and revisiting our current concept
of the pathophysiology behind the sepsis syndrome
[1,29].
Figure 2 Electrolyte levels during experimental sepsis. Plasma samples were obtained and evaluated with a standardized chemistry analyzer
for electrolyte levels as a function of time after CLP. Healthy animals served as negative controls. Electrolytes assessed include sodium (A),
potassium (B), chloride (C), and magnesium (D). n = 5-10 per experimental condition.
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genous glucocorticoids are being released, presumably in
an attempt to modulate and counterbalance the synthesis
and release of inflammatory mediators on a cellular level
[13]. However, vascular and ischemic damage, inflamma-
tion, and apoptosis within the HPA-axis itself [30] can
severely impair the HPA-axis and prompt adrenal insuffi-
ciency, a well-described complication during sepsis [31].
Glucocorticoid insufficiency may result in an imbalanced
T-cell response with uncontrolled systemic inflammation
[32]. If unrecognized and untreated, impaired HPA axis
function may result in a lethal outcome [33,34]. Thus,
current recommendations advocate the use of corticos-
teroids in critically ill patients with adrenal insufficiency
[35]. However, in a large clinical trial, high-dose corticos-
teroids significantly increased morbidity and is therefore
considered obsolete for the treatment of severe sepsis
and septic shock [36]. As a result, current recommenda-
tions suggest the use of moderate doses of corticosteroids
in septic patients [35]. Nonetheless, glucocorticoid sub-
stitution in the septic patient remains a matter of lively
debate [37], as previous studies used different methodol-
ogy (± ACTH test or not), and study group characteris-
tics (sepsis vs. septic shock). This is likely due to the fact
that sepsis-induced adrenal insufficiency seems to be
highly multifactorial and is associated with a very com-
plex and poorly understood pathophysiology.
In the present study, we investigated the function of the
HPA-axis as a function of time after experimental, CLP-
induced sepsis. Focusing on ACTH, corticosterone, and
the mineralocorticoid aldosterone, we assessed the
dynamic changes of these HPA-axis hormones. In addi-
tion, we sought to assess the changes in plasma electrolyte
homeostasis following CLP. We describe bell-shaped
plasma levels of both, corticosterone and aldosterone (Fig-
ures 1B, C). In septic patients, initial hypercortisolism dur-
ing the early stages of sepsis also has been described and is
usually followed by cortisol insufficiency [18]. Although
there is evidence that, in septic patients, a clear dissocia-
tion between ACTH and cortisol levels exists [38], our
present data imply that, in rodents, the physiologic feed-
back loops of the HPA-axis may be intact during the early
course of experimental sepsis (Figures 1A, B). However,
during the later course of CLP, there is likely breakdown
of the blood-brain barrier with ensuing pituitary dysfunc-
tion, resulting in dissociation of the HPA axis [19]. Such a
breakdown of physiologic barriers will result in extravasa-
tion of inflammatory markers and cells, bacteria, ulti-
mately disrupting the classic HPA feedback mechanisms.
Previous reports have described sepsis-induced plasma
alterations of ACTH and corticosterone concentrations
only during the late stages of sepsis [39,40]. Clinical stu-
dies describe persistent hypercortisolism despite low
ACTH levels in septic humans, which may reflect
breakdown of feedback mechanisms in humans and/or
neuronal or mediator-induced hormonal changes. Our dis-
cordant findings may represent one of the disconnects
observed between rodents and men [41]. For instance, rats
are known to produce glucocorticoids in extra-adrenal
organs as well, which may result in a different steroid
response in experimental sepsis [42].
Sepsis and septic shock are important risk factors for
acute renal failure (ARF) and represent the most impor-
tant trigger for ARF in the ICU [43,44]. Twenty percent
of patients with severe sepsis and 50% of patients with
septic shock have been shown exhibit ARF [45]. In addi-
tion, ARF has previously been described in rats following
CLP [46]. In the current study, we found severe plasma
electrolyte disturbances. Animals displayed significant
hypernatremia following CLP (Figure 2A). Sepsis has
been shown recently to be associated with hypernatremia,
which seemed to serve as an independent predictor for
higher mortality in these patients [47]. It remains to be
determined whether the alterations of especially sodium
and potassium levels observed in our study are indeed a
result of ARF or rather represent a downstream effect of
the significantly increased aldosterone levels found in
septic animals (Figure 1C). In the present study, septic
rats also exhibited severe hypomagnesemia (Figure 2D),
which also has been described in up to 65% of ICU
patients [48,49]. More importantly, magnesium defi-
ciency in the ICU is associated with prolonged hospitali-
zation [50], two- to threefold higher mortality rates, and
the development of sepsis [51]. An experimental study
revealed that magnesium administration reduced the
severity of septic encephalopathy [52], which represents a
serious complication of sepsis in the ICU with high mor-
bidity and mortality [53]. In this study, animals treated
with magnesium sulfate displayed attenuated blood-brain
barrier breakdown and reduced brain edema compared
with vehicle-treated septic littermates [52].
Our study has several shortcomings. First, the animal
model did not use any resuscitative measure or antibio-
tic coverage but only studied the natural course of dis-
ease. This limits the transferability of our findings into
the human setting even more in addition to the tradi-
tional, well-described disconnect between humans and
rodents [41]. Second, we did not provide a true hormo-
nal time-course for sham controls. However, plasma
samples were obtained exactly at the same time of the
day for all experiments to account for the circadian
rhythm of HPA axis hormones. Thus, it was assumed
that sham animals maintained an intact HPA axis. In
addition, our study is merely descriptive and fails to
unravel any molecular mechanisms involved in the
breakdown of the HPA axis in sepsis. Complement C5a
m a yp l a ya ni m p o r t a n tr o l ei nt h ep a t h o g e n e s i so ft h e
HPA disturbance [19]. Nevertheless, our study provides
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HPA axis.
Conclusions
Sepsis continues to be a poorly understood syndrome.
To be able to develop novel therapeutic approaches, we
have to broaden our understanding about its intricate
and multimodal pathophysiology. Disturbances of the
H P Aa x i sa n di t sh o r m o n e sm a yc o n t r i b u t et os e v e r a l
severe complications encountered in the septic patient.
Thus, consecutive studies need to be designed to further
unravel the complex cross-talk between the HPA axis
and the immune response.
Acknowledgements
This study was supported by NIH grants GM29507, GM61656, and HL-31963
(to PAW) and Deutsche Forschungsgemeinschaft grants DFG HU 823/2-2
and HU 823/2-3 (to MH-L). The funding bodies had no role in study design,
data collection and analysis, decision to publish, or preparation of the
manuscript.
Author details
1Department of Orthopaedics, School of Medicine, University of Colorado,
Denver Health Medical Center, Denver, CO, 80204, USA
2Department of
Trauma Surgery, University Hospital Zurich, Zurich, Switzerland
3Department
of Trauma, Hand-, Plastic-, and Reconstructive Surgery, University Hospital
Ulm, Ulm, 89075, Germany
4Department of Pathology, University of Michigan
Medical School, Ann Arbor, MI, 48109, USA
5Department of Neurosurgery,
University of Colorado, School of Medicine, Denver Health Medical Center,
Denver, CO, 80204, USA
Authors’ contributions
MAF, PFS, MHL, and PAW designed the study and supervised the
experiments. MAF and DR performed all experiments. MAF, PFS, SJM, and
WRS analyzed the data and drafted the manuscript. All authors revised the
manuscript for important scientific content, read, and approved the final
manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 29 September 2011 Accepted: 30 December 2011
Published: 30 December 2011
References
1. Rittirsch D, Flierl MA, Ward PA: Harmful molecular mechanisms in sepsis.
Nat Rev Immunol 2008, 8(10):776-787.
2. Dombrovskiy VY, Martin AA, Sunderram J, Paz HL: Rapid increase in
hospitalization and mortality rates for severe sepsis in the United States:
a trend analysis from 1993 to 2003. Crit Care Med 2007, 35(5):1244-1250.
3. Kung HC, Hoyert DL, Xu J, Murphy SL: Deaths: final data for 2005. Natl
Vital Stat Rep 2008, 56(10):1-120.
4. Annane D, Vignon P, Renault A, Bollaert PE, Charpentier C, Martin C,
Troche G, Ricard JD, Nitenberg G, Papazian L, et al: Norepinephrine plus
dobutamine versus epinephrine alone for management of septic shock:
a randomised trial. Lancet 2007, 370(9588):676-684.
5. Zeiher BG, Steingrub J, Laterre PF, Dmitrienko A, Fukiishi Y, Abraham E:
LY315920NA/S-5920, a selective inhibitor of group IIA secretory
phospholipase A2, fails to improve clinical outcome for patients with
severe sepsis. Crit Care Med 2005, 33(8):1741-1748.
6. Werdan K, Pilz G, Bujdoso O, Fraunberger P, Neeser G, Schmieder RE, Viell B,
Marget W, Seewald M, Walger P, et al: Score-based immunoglobulin G
therapy of patients with sepsis: the SBITS study. Crit Care Med 2007,
35(12):2693-2701.
7. Bone RC, Balk RA, Fein AM, Perl TM, Wenzel RP, Reines HD, Quenzer RW,
Iberti TJ, Macintyre N, Schein RM: A second large controlled clinical study
of E5, a monoclonal antibody to endotoxin: results of a prospective,
multicenter, randomized, controlled trial. The E5 Sepsis Study Group. Crit
Care Med 1995, 23(6):994-1006.
8. Abraham E, Wunderink R, Silverman H, Perl TM, Nasraway S, Levy H, Bone R,
Wenzel RP, Balk R, Allred R, et al: Efficacy and safety of monoclonal
antibody to human tumor necrosis factor alpha in patients with sepsis
syndrome. A randomized, controlled, double-blind, multicenter clinical
trial. TNF-alpha MAb Sepsis Study Group. JAMA 1995, 273(12):934-941.
9. Greenman RL, Schein RM, Martin MA, Wenzel RP, MacIntyre NR,
Emmanuel G, Chmel H, Kohler RB, McCarthy M, Plouffe J, et al: A controlled
clinical trial of E5 murine monoclonal IgM antibody to endotoxin in the
treatment of gram-negative sepsis. The XOMA Sepsis Study Group. JAMA
1991, 266(8):1097-1102.
10. Westphal M, Ertmer C: Dear sepsis trials, why do you like playing tricks
on us? Curr Opin Anaesthesiol 2008, 21(2):95-97.
11. Vincent JL: Search for effective immunomodulating strategies against
sepsis. Lancet 1998, 351(9107):922-923.
12. Rivers E, Nguyen B, Havstad S, Ressler J, Muzzin A, Knoblich B, Peterson E,
Tomlanovich M: Early goal-directed therapy in the treatment of severe
sepsis and septic shock. N Engl J Med 2001, 345(19):1368-1377.
13. Sternberg EM: Neural regulation of innate immunity: a coordinated
nonspecific host response to pathogens. Nat Rev Immunol 2006,
6(4):318-328.
14. Tracey KJ: The inflammatory reflex. Nature 2002, 420(6917):853-859.
15. Elenkov IJ, Wilder RL, Chrousos GP, Vizi ES: The sympathetic nerve–an
integrative interface between two supersystems: the brain and the
immune system. Pharmacol Rev 2000, 52(4):595-638.
16. Weinberg PF, Matthay MA, Webster RO, Roskos KV, Goldstein IM, Murray JF:
Biologically active products of complement and acute lung injury in
patients with the sepsis syndrome. Am Rev Respir Dis 1984,
130(5):791-796.
17. Brierre S, Kumari R, Deboisblanc BP: The endocrine system during sepsis.
Am J Med Sci 2004, 328(4):238-247.
18. Maxime V, Siami S, Annane D: Metabolism modulators in sepsis: the
abnormal pituitary response. Crit Care Med 2007, 35(9 Suppl):S596-S601.
19. Flierl MA, Stahel PF, Rittirsch D, Huber-Lang M, Niederbichler AD,
Hoesel LM, Touban BM, Morgan SJ, Smith WR, Ward PA, et al: Inhibition of
complement C5a prevents breakdown of the blood-brain barrier and
pituitary dysfunction in experimental sepsis. Crit Care 2009, 13(1):R12.
20. Vermes I, Beishuizen A, Hampsink RM, Haanen C: Dissociation of plasma
adrenocorticotropin and cortisol levels in critically ill patients: possible
role of endothelin and atrial natriuretic hormone. J Clin Endocrinol Metab
1995, 80(4):1238-1242.
21. Manglik S, Flores E, Lubarsky L, Fernandez F, Chhibber VL, Tayek JA:
Glucocorticoid insufficiency in patients who present to the hospital with
severe sepsis: a prospective clinical trial. Crit Care Med 2003,
31(6):1668-1675.
22. Baker CC, Chaudry IH, Gaines HO, Baue AE: Evaluation of factors affecting
mortality rate after sepsis in a murine cecal ligation and puncture
model. Surgery 1983, 94(2):331-335.
23. Rittirsch D, Huber-Lang MS, Flierl MA, Ward PA: Immunodesign of
experimental sepsis by cecal ligation and puncture. Nat Protoc 2009,
4(1):31-36.
24. Solberg LC, Olson SL, Turek FW, Redei E: Altered hormone levels and
circadian rhythm of activity in the WKY rat, a putative animal model of
depression. Am J Physiol Regul Integr Comp Physiol 2001, 281(3):R786-R794.
25. Brady KT, Sonne SC: The role of stress in alcohol use, alcoholism
treatment, and relapse. Alcohol Res Health 1999, 23(4):263-271.
26. Martin GS, Mannino DM, Eaton S, Moss M: The epidemiology of sepsis in
the United States from 1979 through 2000. N Engl J Med 2003,
348(16):1546-1554.
27. Bone RC: Sir Isaac Newton, sepsis, SIRS, and CARS. Crit Care Med 1996,
24(7):1125-1128.
28. Vincent JL: Dear SIRS, I’m sorry to say that I don’t like you. Crit Care Med
1997, 25(2):372-374.
29. Remick DG: Pathophysiology of sepsis. Am J Pathol 2007,
170(5):1435-1444.
30. Sharshar T, Gray F, Lorin de la Grandmaison G, Hopkinson NS, Ross E,
Dorandeu A, Orlikowski D, Raphael JC, Gajdos P, Annane D: Apoptosis of
neurons in cardiovascular autonomic centres triggered by inducible
Flierl et al. Annals of Intensive Care 2011, 1:53
http://www.annalsofintensivecare.com/content/1/1/53
Page 6 of 7nitric oxide synthase after death from septic shock. Lancet 2003,
362(9398):1799-1805.
31. Annane D: Adrenal insufficiency in sepsis. Curr Pharm Des 2008,
14(19):1882-1886.
32. Annane D, Sebille V, Bellissant E: Effect of low doses of corticosteroids in
septic shock patients with or without early acute respiratory distress
syndrome. Crit Care Med 2006, 34(1):22-30.
33. Rothwell PM, Udwadia ZF, Lawler PG: Cortisol response to corticotropin
and survival in septic shock. Lancet 1991, 337(8741):582-583.
34. Annane D, Sebille V, Troche G, Raphael JC, Gajdos P, Bellissant E: A 3-level
prognostic classification in septic shock based on cortisol levels and
cortisol response to corticotropin. JAMA 2000, 283(8):1038-1045.
35. Marik PE, Pastores SM, Annane D, Meduri GU, Sprung CL, Arlt W, Keh D,
Briegel J, Beishuizen A, Dimopoulou I, et al: Recommendations for the
diagnosis and management of corticosteroid insufficiency in critically ill
adult patients: consensus statements from an international task force by
the American College of Critical Care Medicine. Crit Care Med 2008,
36(6):1937-1949.
36. Bone RC, Fisher CJ Jr, Clemmer TP, Slotman GJ, Metz CA, Balk RA: A
controlled clinical trial of high-dose methylprednisolone in the
treatment of severe sepsis and septic shock. N Engl J Med 1987,
317(11):653-658.
37. Fernandes D, Duma D, Assreuy J: Steroids and nitric oxide in sepsis. Front
Biosci 2008, 13:1698-1710.
38. Loisa P, Rinne T, Kaukinen S: Adrenocortical function and multiple organ
failure in severe sepsis. Acta Anaesthesiol Scand 2002, 46(2):145-151.
39. Koo DJ, Jackman D, Chaudry IH, Wang P: Adrenal insufficiency during the
late stage of polymicrobial sepsis. Crit Care Med 2001, 29(3):618-622.
40. Carlson DE, Chiu WC, Scalea TM: Cecal ligation and puncture in rats
interrupts the circadian rhythms of corticosterone and adrenocortical
responsiveness to adrenocorticotrophic hormone. Crit Care Med 2006,
34(4):1178-1184.
41. Rittirsch D, Hoesel LM, Ward PA: The disconnect between animal models
of sepsis and human sepsis. J Leukoc Biol 2007, 81(1):137-143.
42. Silvestre JS, Robert V, Heymes C, Aupetit-Faisant B, Mouas C, Moalic JM,
Swynghedauw B, Delcayre C: Myocardial production of aldosterone and
corticosterone in the rat. Physiological regulation. J Biol Chem 1998,
273(9):4883-4891.
43. Silvester W, Bellomo R, Cole L: Epidemiology, management, and outcome
of severe acute renal failure of critical illness in Australia. Crit Care Med
2001, 29(10):1910-1915.
44. Brivet FG, Kleinknecht DJ, Loirat P, Landais PJ: Acute renal failure in
intensive care units–causes, outcome, and prognostic factors of hospital
mortality; a prospective, multicenter study. French Study Group on
Acute Renal Failure. Crit Care Med 1996, 24(2):192-198.
45. Rangel-Frausto MS, Pittet D, Costigan M, Hwang T, Davis CS, Wenzel RP:
The natural history of the systemic inflammatory response syndrome
(SIRS). A prospective study. JAMA 1995, 273(2):117-123.
46. Huber-Lang M, Sarma VJ, Lu KT, McGuire SR, Padgaonkar VA, Guo RF,
Younkin EM, Kunkel RG, Ding J, Erickson R, et al: Role of C5a in multiorgan
failure during sepsis. J Immunol 2001, 166(2):1193-1199.
47. Hoorn EJ, Betjes MG, Weigel J, Zietse R: Hypernatraemia in critically ill
patients: too little water and too much salt. Nephrol Dial Transplant 2008,
23(5):1562-1568.
48. Ryzen E, Wagers PW, Singer FR, Rude RK: Magnesium deficiency in a
medical ICU population. Crit Care Med 1985, 13(1):19-21.
49. Reinhart RA, Desbiens NA: Hypomagnesemia in patients entering the ICU.
Crit Care Med 1985, 13(6):506-507.
50. Fiaccadori E, Del Canale S, Coffrini E, Melej R, Vitali P, Guariglia A,
Borghetti A: Muscle and serum magnesium in pulmonary intensive care
unit patients. Crit Care Med 1988, 16(8):751-760.
51. Soliman HM, Mercan D, Lobo SS, Melot C, Vincent JL: Development of
ionized hypomagnesemia is associated with higher mortality rates. Crit
Care Med 2003, 31(4):1082-1087.
52. Esen F, Erdem T, Aktan D, Orhan M, Kaya M, Eraksoy H, Cakar N, Telci L:
Effect of magnesium sulfate administration on blood-brain barrier in a
rat model of intraperitoneal sepsis: a randomized controlled
experimental study. Crit Care 2005, 9(1):R18-R23.
53. Siami S, Annane D, Sharshar T: The encephalopathy in sepsis. Crit Care Clin
2008, 24(1):67-82, viii.
doi:10.1186/2110-5820-1-53
Cite this article as: Flierl et al.: Disturbances of the hypothalamic-
pituitary-adrenal axis and plasma electrolytes during experimental
sepsis. Annals of Intensive Care 2011 1:53.
Submit your manuscript to a 
journal and beneﬁ  t from:
7 Convenient online submission
7 Rigorous peer review
7 Immediate publication on acceptance
7 Open access: articles freely available online
7 High visibility within the ﬁ  eld
7 Retaining the copyright to your article
    Submit your next manuscript at 7 springeropen.com
Flierl et al. Annals of Intensive Care 2011, 1:53
http://www.annalsofintensivecare.com/content/1/1/53
Page 7 of 7